In the Journal of the American Chemical Society, researchers from KTH Royal Institute of Technology*, Karolinska Institutet and Karolinska University Hospital recently published a study on dendritic hydrogels and their ability to fight drug-resistant bacteria. This antibiotic-free material shows excellent antibacterial qualities and were effective against a broad spectrum of clinical bacteria, as well as inducing the body’s own immune response.
The hydrogels were based on PEG and Bis-MPA hyperbranched dendritic polymers, which are the same kind Polymer Factory specializes in; this shows yet another exciting area of application for these advanced and diverse materials.
Find the article HERE
Polymer Factory are proud to offer materials that are associated with the cutting-edge research within dendritic materials and ongoing advances in antibacterial materials.
*Note: The research that was conducted belonged to Prof. Michael Malkoch at KTH, the Malkoch Group, and was not influenced or sponsored by Polymer Factory. Prof. Malkoch is the CTO of Polymer Factory.
Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from Big Pharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company’s dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g., a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company’s dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.